EMA Clarifies Adverse Events for Off-Label Drug Use

International Pharmaceutical Regulatory Monitor
A A
Drugmakers are expected to collect individual cases of suspected adverse reactions linked to off-label use but not individual reports when there has been no associated adverse event, the EMA said in April.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor